| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| Other Sizes |
| Targets |
3-Azetidinemethanol hydrochloride is a pharmaceutical intermediate used in the synthesis of SHP2 inhibitors and human rhinovirus inhibitors. It does not have a specific target itself. It is used as a building block to introduce the azetidine moiety into drug molecules.
|
|---|---|
| ln Vitro |
3-Azetidinemethanol hydrochloride is a building block used in the synthesis of other compounds. Its in vitro activity is assessed as part of the final synthesized compounds, such as SHP2 inhibitors. It is not typically tested for biological activity on its own.
|
| ln Vivo |
3-Azetidinemethanol hydrochloride is used as an intermediate in the synthesis of compounds with in vivo activity, such as SHP2 inhibitors. The in vivo activity is assessed for the final drug compounds.
|
| Enzyme Assay |
3-Azetidinemethanol hydrochloride is used as a starting material or intermediate in chemical synthesis. Its purity and identity are confirmed by standard analytical techniques such as NMR and HPLC.
|
| Cell Assay |
3-Azetidinemethanol hydrochloride is used in the synthesis of compounds that are tested in cell-based assays. It is not typically tested directly in cell-based assays.
|
| Animal Protocol |
3-Azetidinemethanol hydrochloride is used in the synthesis of compounds that are tested in animal models. It is not typically tested directly in animal models.
|
| ADME/Pharmacokinetics |
3-Azetidinemethanol hydrochloride has a molecular weight of 123.58 g/mol and a molecular formula of C4H10ClNO. It is a solid at room temperature. It is typically used for research purposes only.
|
| Toxicity/Toxicokinetics |
3-Azetidinemethanol hydrochloride is a chemical intermediate. Its toxicological profile is typically evaluated as part of the safety assessment of the final drug compounds.
|
| References | |
| Additional Infomation |
3-Azetidinemethanol hydrochloride (CAS 928038-44-2) is a pharmaceutical intermediate. It has a molecular weight of 123.58 and a molecular formula of C4H10ClNO. It is used in the synthesis of SHP2 and human rhinovirus inhibitors. It is not approved for clinical use and is available only for research purposes.
|
| Molecular Formula |
C4H10CLNO
|
|---|---|
| Molecular Weight |
123.58
|
| Exact Mass |
123.045
|
| CAS # |
928038-44-2
|
| PubChem CID |
24801400
|
| Appearance |
White to light yellow solid powder
|
| LogP |
0.328
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
7
|
| Complexity |
42.8
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1C(CN1)CO.Cl
|
| InChi Key |
AQUVQGSNKVDBBF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C4H9NO.ClH/c6-3-4-1-5-2-4;/h4-6H,1-3H2;1H
|
| Chemical Name |
azetidin-3-ylmethanol;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (809.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (20.23 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (20.23 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (20.23 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.0919 mL | 40.4596 mL | 80.9192 mL | |
| 5 mM | 1.6184 mL | 8.0919 mL | 16.1838 mL | |
| 10 mM | 0.8092 mL | 4.0460 mL | 8.0919 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
